Discontinued Drugs in 2005 - Featured Series of Reports From Expert Opinion.
LONDON, October 17 /PRNewswire/ -- The current issue of Expert Opinion on Investigational Drugs features the first in a series of reports by key opinion leaders analysing discontinued drugs in 2005.
Dr Keith Suckling (formerly GlaxoSmithKline, UK) provides his expert opinion on cardiovascular drugs that were dropped from clinical development in 2005; and Professor Lloyd Kelland (Head of Biology, Wolfson Institute for Biomedical Research, University College London “UCL” redirects here. For other uses, see UCL (disambiguation).
University College London, commonly known as UCL, is the oldest multi-faculty constituent college of the University of London, one of the two original founding colleges, and the first British ) discusses the 20 drugs discontinued in 2005 in the field of oncology.
These will be followed in later issues by papers on pulmonary, dermatological, gastrointestinal and arthritis drugs by Professor Kenneth KC Lee (The Chinese University of Hong Kong The motto of the university is "博文約禮" in Chinese, meaning "to broaden one's intellectual horizon and keep within the bounds of propriety". ); drugs for disorders of the central nervous system by Professor Robert Kerwin (Professor of Clinical Neuropharmacology neuropharmacology /neu·ro·phar·ma·col·o·gy/ (-fahr?mah-kol´ah-je) the scientific study of the effects of drugs on the nervous system.
n. , Institute of Psychiatry The Institute of Psychiatry (IOP) is a research institution dedicated to discovering what causes mental health problems and diseases of the brain. In addition, its aim is to help identify new treatments for them and ways to prevent them in the first place. , King's College London); anti-infectives by Dr Nafsika Georgopapadakou (MethylGene); and renal, endocrine and metabolic drugs by Dr Jerry Colca (Kalamazoo Metabolic Research).
The series of papers is introduced by an editorial, featured in the November issue, by Dr Louis A Tartaglia (Senior Vice President and General Manager, Drug Repositioning and Selection, Gene Logic) on the value of drug repositioning.
Data from the Pharmaprojects drug R&D pipeline database estimates around 100 compounds are discontinued every year, at an enormous cost to the pharmaceutical industry. There is clearly a need to identify the reasons for these failures and develop better and more efficient methods to avoid such losses in future.
TARTAGLIA LA: Complementary new approaches enable repositioning of failed drug candidates. Expert Opin. Investig. Drugs (2006) 15(11):1295-1298 doi:10.1517/135437184.108.40.2065 http://www.expertopin.com/doi/abs/10.1517/135437220.127.116.115
SUCKLING K: Discontinued drugs in 2005: cardiovascular drugs. Expert Opin. Investig. Drugs (2006) 15(11):1299-1308 doi:10.1517/13543718.104.22.1689 http://www.expertopin.com/doi/abs/10.1517/13543722.214.171.1249
KELLAND L: Discontinued drugs in 2005: oncology drugs. Expert Opin. Investig. Drugs (2006) 15(11):1309-1318 doi:10.1517/135437126.96.36.1999 http://www.expertopin.com/doi/abs/10.1517/135437188.8.131.529
About Expert Opinion
For over a decade, the Expert Opinion series has provided systematic and authoritative reviews to support every stage of the drug discovery and R&D pipeline from target to market. Each of the ten journals in the series covers a specific aspect of the pharmaceutical pipeline.
The series contains the following journals: Expert Opinion on Biological Therapy, Expert Opinion on Drug Delivery, Expert Opinion on Drug Metabolism Drug Metabolism/Interactions Definition
Drug metabolism is the process by which the body breaks down and converts medication into active chemical substances.
Drugs can interact with other drugs, foods, and beverages. & Toxicology, Expert Opinion on Drug Safety, Expert Opinion on Emerging Drugs, Expert Opinion on Investigational Drugs, Expert Opinion on Pharmacotherapy pharmacotherapy /phar·ma·co·ther·a·py/ (-ther´ah-pe) treatment of disease with medicines.
Treatment of disease through the use of drugs. , Expert Opinion on Therapeutic Patents, Expert Opinion on Therapeutic Targets and Expert Opinion on Drug Discovery.
For further information: Phil Garner, Publisher Telephone: +44-(0)20-7017-6775 Email: email@example.com Website: http://www.expertopin.com/
CONTACT: For further information: Phil Garner, Publisher, Telephone: +44-(0)20-7017-6775, Email: firstname.lastname@example.org, Website: http://www.expertopin.com/